Naphthyl sulfonamide derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
申请人:SANOFI
公开号:EP2998292A1
公开(公告)日:2016-03-23
The present invention relates to naphthyl sulfonamide derivatives of the formula I
in which R1, R2, R3, R4, R5, R6, R10, A, D, X, q, i, n, L and R50 are defined as indicated below.
The naphthyl sulfonamide derivatives I are KEAP-1 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders, neuroinflammatory and neurodegenerative diseases, such as multiple sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's disease. The invention furthermore relates to the use of naphthyl sulfonamide derivatives of the formula I or II as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
本发明涉及式I的萘磺酰胺衍生物,其中R1、R2、R3、R4、R5、R6、R10、A、D、X、q、i、n、L和R50的定义如下。 萘磺酰胺衍生物I是KEAP-1调节剂,用于预防和/或治疗糖尿病、肥胖、血脂异常及相关疾病,神经炎症和神经退行性疾病,如多发性硬化症、阿尔茨海默病、帕金森病和亨廷顿病。 本发明还涉及将式I或II的萘磺酰胺衍生物用作药物的活性成分,以及包含它们的药物组合物。